2F-DCK (2-Fluorodeschloroketamine): Complete Toxicology, Deaths, Dependence & Safety Monograph

2F-DCK (2-Fluorodeschloroketamine): Complete Toxicology, Deaths, Dependence & Safety Monograph

Emergency dissociative toxicity: Seizure, loss of consciousness, severe confusion/agitation, dangerous self-injury, abnormal breathing, collapse, chest pain, or inability to safely care for oneself after 2F-DCK or an unknown dissociative warrants urgent medical evaluation.

Quick answer

2F-DCK is a fluorinated ketamine analogue with documented human poisonings, severe behavioral toxicity, and deaths.

It is also called:

• 2-FDCK;
• 2-fluorodeschloroketamine;
• 2-fluorodeschloroketamine.

The clinical evidence is stronger than its “research chemical” label suggests:

• a 20-case analytically confirmed hospital series;
• severe dissociation with loss of consciousness/convulsions;
• published deaths;
• a self-mutilation case;
• extensive human metabolism work;
• chronic-use hair/urine evidence.

Identity

History and emergence

2F-DCK was first reported to international NPS monitoring around 2016 and subsequently appeared across multiple countries.

By 2019 it had emerged in a Hong Kong poisoning cluster.

WHO reviewed the compound, and in March 2024 the UN Commission on Narcotic Drugs voted to place it in Schedule II of the 1971 Convention.

The U.S. then initiated treaty-related and public-safety scheduling proceedings, culminating in temporary Schedule I control in May 2026.

Pharmacology

2F-DCK belongs to the ketamine-like arylcyclohexylamines.

The central dissociative mechanism is NMDA receptor antagonism, which reduces glutamatergic signaling.

Possible effects include:

• dissociation;
• analgesia;
• altered perception;
• impaired memory;
• ataxia;
• reduced responsiveness;
• confusion;
• abnormal behavior;
• loss of consciousness.

Fluorinated ketamine is not simply “ketamine with a fixed multiplier”

A single fluorine substitution can alter:

• metabolism;
• clearance;
• receptor interactions;
• duration;
• metabolite formation.

There is no validated human ketamine-equivalence ratio.

The 20-case human poisoning cluster

Between January and July 2019, investigators identified 20 analytically confirmed 2F-DCK exposures.

Clinical effects were predominantly:

Neurologic

• impaired consciousness;
• agitation;
• abnormal behavior.

Cardiovascular

• hypertension;
• tachycardia.

Five patients experienced loss of consciousness or convulsion.

All recovered with mainly supportive care.

Major limitation: nearly everyone had other ketamine analogues

In 19 of 20 cases, at least one additional ketamine-type drug was detected.

Common co-detections included:

• ketamine: 90%;
• deschloroketamine: 50%;
• O-PCE: 45%;
• tiletamine: 10%.

Six patients had four ketamine-type drugs in the same urine sample.

Therefore the cluster establishes that 2F-DCK is part of serious intoxication presentations—but does not let us assign a clean percentage of each symptom to 2F-DCK alone.

Severe dissociation and self-injury

A 2024 forensic report described:

• one severe self-mutilation case;
• two deaths associated with 2F-DCK exposure.

The self-injury case underscores a major dissociative hazard:

a person can become severely disconnected from pain, body integrity, environment and risk while still capable of complex behavior.

This is not merely a “bad trip” in the colloquial sense; severe dissociation can create major trauma risk.

Fatality evidence

Two-death/self-mutilation series

The 2024 report quantified 2F-DCK and metabolites in blood, urine and hair.

One fatal case had a particularly high peripheral-blood concentration, but postmortem concentration cannot be converted into a personal lethal dose.

Earlier multidrug fatality

A 2021 case involved:

• 2F-DCK;
• 3-MeO-PCE;
• 5-MeO-DMT;
• amphetamine;
• cocaine;
• evidence of additional drug use.

Investigators considered the death the result of a combined “cocktail” effect with 2F-DCK as a major contributor.

This case is strong evidence of forensic relevance but weak evidence for an isolated-drug lethal threshold.

Metabolism: far more complex than parent drug alone

A 2023 high-resolution mass-spectrometry study characterized 26 putative 2F-DCK metabolites, 15 newly reported in that work.

Authentic urine and hair from a chronic/addicted user confirmed multiple metabolites.

Useful targets included:

• nor-2F-DCK;
• OH-dihydro-nor-2F-DCK;
• dehydro-nor-2F-DCK;
• additional hydroxylated/reduced products.

Can 2F-DCK metabolize into DCK?

Evidence increasingly supports deschloroketamine (DCK) as a 2F-DCK metabolite.

The 2023 chronic-use study identified DCK in biological samples and in-vitro systems.

The 2024 forensic series also found DCK; in one case investigators considered metabolic formation plausible where separate DCK use was not established.

Why this matters

DCK detection does not always prove DCK was independently consumed.

Interpretation must consider:

• 2F-DCK metabolism;
• seized-product contamination;
• independent DCK use;
• specimen timing.

Earlier metabolite work

A 2020 clinical study identified putative metabolites including:

• nor-2F-DCK;
• dehydronor-2F-DCK;
• hydroxylated nor-2F-DCK derivatives.

A 2021 molecular-networking study found additional phase-I and phase-II products in postmortem samples.

Together these studies make metabolite-aware testing much stronger than parent-only analysis.

Pharmacokinetics: what is still missing

There is not yet a robust controlled human PK program defining:

• bioavailability by route;
• time to peak;
• population half-life;
• repeated-use accumulation;
• active-metabolite contribution;
• dose-concentration relationships.

In-vitro/in-vivo extrapolation studies improve predictions but do not replace controlled human pharmacokinetics.

Acute toxicity

Potential severe effects include:

• profound dissociation;
• confusion;
• agitation;
• ataxia;
• impaired consciousness;
• convulsions;
• hypertension;
• tachycardia;
• vomiting/aspiration risk;
• injury;
• respiratory compromise in severe/mixed exposure;
• death.

Interactions

Other dissociatives

Can compound:

• loss of consciousness;
• motor impairment;
• hypertension;
• amnesia;
• delirium;
• injury risk.

This is especially relevant because the 2019 series showed extremely frequent co-use of ketamine analogues.

Alcohol/benzodiazepines/opioids

Can increase:

• CNS depression;
• aspiration risk;
• respiratory compromise;
• accidents.

Stimulants

Can add cardiovascular stress without restoring judgment or coordination.

Psychedelics

Can intensify perceptual/cognitive disorganization and behavioral unpredictability.

Tolerance and repeated exposure

Repeated NMDA-receptor-antagonist exposure can produce tolerance to some dissociative effects.

For 2F-DCK specifically, controlled human studies have not established:

• a typical tolerance-development timeline;
• a reliable cross-tolerance ratio with ketamine, DCK, O-PCE, or PCP analogues;
• how tolerance changes urinary, bladder, cognitive, hepatic, or accident risk;
• a dose-escalation level that remains safe.

A person feeling less dissociated after repeated exposure may still have meaningful psychomotor impairment or accumulating organ/behavioral risk.

Tolerance therefore should not be used as a rationale for escalating an unregulated dissociative.

Dependence and compulsive use

A 2023 metabolism study specifically analyzed urine and hair from an addicted/chronic 2F-DCK user, providing direct evidence that problematic repeated exposure occurs.

That is not enough to calculate prevalence.

But it moves dependence liability beyond pure analogy.

Possible use-disorder features include:

• craving;
• escalating use;
• inability to cut down;
• frequent dissociative intoxication;
• continued use despite injury or urinary/psychiatric problems.

Withdrawal

There is no validated 2F-DCK-specific withdrawal syndrome timeline.

Ketamine/dissociative withdrawal after heavy repeated use may involve:

• craving;
• anxiety;
• low mood;
• irritability;
• sleep disturbance;
• restlessness.

Severe psychiatric symptoms or suicidality require clinical assessment.

Unlike benzodiazepine withdrawal, there is no evidence that a stereotyped seizure/delirium withdrawal syndrome defines 2F-DCK cessation.

Ketamine-class urinary toxicity

Chronic ketamine use can cause serious ketamine-induced cystitis/uropathy.

Symptoms include:

• urinary frequency;
• urgency;
• painful urination;
• bladder/pelvic pain;
• blood in urine;
• reduced bladder capacity;
• upper urinary-tract damage in advanced disease.

French and British 2024 guidance emphasizes early recognition and stopping ketamine exposure.

Does 2F-DCK have the same cystitis incidence?

Unknown.

There is not enough compound-specific longitudinal evidence to quantify 2F-DCK bladder risk.

Persistent urinary symptoms after frequent 2F-DCK use should still prompt medical evaluation because:

• it is a ketamine analogue;
• chronic exposure is documented;
• ketamine uropathy can progress if ignored.

This is class-informed caution, not a claim of identical risk.

Treatment and support

There is no medication approved specifically for 2F-DCK use disorder or withdrawal.

Care can include:

• supportive management of acute intoxication;
• seizure/injury/cardiovascular treatment;
• psychiatric evaluation for severe behavioral effects;
• addiction treatment for compulsive use;
• urologic evaluation for urinary symptoms.

U.S. support:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

Drug testing

Routine screens

Standard immunoassays should not be assumed to identify 2F-DCK.

A person can have a major dissociative intoxication while ordinary toxicology panels fail to name the agent.

Definitive testing

Useful approaches include:

• LC-MS/MS;
• LC-HRMS/QTOF;
• validated GC-MS methods;
• parent + metabolite targets;
• hair testing for longer-term exposure.

Why metabolite choice matters

Nor-2F-DCK and other metabolites may extend detection when parent drug is low or absent.

Because DCK can arise metabolically, analytical interpretation should not simply convert every DCK result into proof of separate DCK consumption.

Hair testing

Hair can document longer-term exposure history.

It is useful for patterns over weeks/months, not for determining whether a person was acutely impaired at a particular hour.

The 2023 chronic-use case found 2F-DCK, DCK and multiple metabolites in segmented hair.

Forensic interpretation

Fatal blood concentration ≠ lethal dose

The two-death series provides valuable concentration data.

It does not establish a universal lethal threshold.

Detection ≠ sole causation

One death can involve:

• another dissociative;
• stimulant;
• psychedelic;
• trauma;
• underlying disease.

Putrefaction and specimen quality

Advanced decomposition, as present in one reported death, complicates concentration interpretation.

Metabolism vs co-use

DCK can reflect metabolism or separate use.

Scene evidence and product testing matter.

Special populations

Controlled data are inadequate for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• cardiovascular disease;
• seizure disorders;
• psychiatric illness;
• liver/kidney disease.

People with prior seizures or severe psychiatric illness may face heightened concern from a drug that can produce convulsions and profound dissociation, although exact risk magnitudes are not quantified.

Legal and regulatory history

International

At the 67th UN Commission on Narcotic Drugs session on March 19, 2024, countries voted to place 2F-DCK in Schedule II of the 1971 Convention on Psychotropic Substances.

United States

DEA published a notice of intent in January 2026.

DEA then issued a temporary scheduling order placing 2F-DCK, its salts and relevant isomers in Schedule I effective May 22, 2026, DEA code 7284.

Temporary scheduling remains effective for the statutory temporary-control period unless extended or superseded by permanent action.

Myths and misconceptions

“2F-DCK is just ketamine with fluorine, so the effects are predictable.”
False. Human poisonings, metabolism and duration differ.

“A negative ketamine screen rules it out.”
False. Novel arylcyclohexylamines frequently require targeted mass spectrometry.

“DCK in a sample always means the person also took DCK.”
Not necessarily. DCK can be a 2F-DCK metabolite.

“A concentration from a death tells me a lethal dose.”
False.

“Bladder damage is proven to occur at the same rate as ketamine.”
No. Ketamine uropathy is established; 2F-DCK-specific incidence remains unknown.

“No formal withdrawal trial means it cannot be addictive.”
False. Chronic/addicted use is documented; the exact incidence and withdrawal course are the uncertain parts.

Evidence ledger

Related evidence

• O-PCE / 2-Oxo-PCE
• Deschloroketamine / DCK
• Ketamine
• Methoxetamine / MXE
• Dissociatives & arylcyclohexylamines guide
• Substance Use, Dependence & Harm Reduction hub

Bottom line

2F-DCK is no longer a barely characterized ketamine analogue.

Human clinical series, deaths, chronic-use samples and extensive metabolism studies now establish a real toxicology profile.

The biggest remaining gaps are exactly the ones shallow RC pages tend to fill with guesses: controlled human PK, dependence incidence, withdrawal timing and long-term bladder/organ risk.

Those should remain explicitly unknown rather than being copied from ketamine.